Please select an event

Select a date :

Select an Event :

ATTENDEE POLICY

CSL Behring complies with PhRMA Guidelines; therefore, spouses, partners, or guests may not attend any meeting or social function. Spouses and guests will not be permitted to attend any activities related to this meeting, including meal functions, as these are considered part of the official program. If your spouse or a guest is traveling with you, any charges or expenses related to his or her presence will be your personal responsibility.

This program is intended for US healthcare providers only.

REPORTING POLICY

Personal information provided above will not be used for any other purpose beyond this peer-to-peer program and required federal and state-level reporting.

Consistent with federal and state reporting obligations including, but not limited to, the Federal Physician Payment Sunshine Act, CSL Behring will disclose any transfers of value given to healthcare providers attending our programs.

Important Safety Information

Kcentra^®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure. Kcentra is for intravenous use only.

WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS

Patients being treated with Vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the risk of thromboembolic events, especially in patients with history of such events. Resumption of anticoagulation therapy should be carefully considered once the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and nonfatal arterial and venous thromboembolic complications have been reported in clinical trials and postmarketing surveillance. Monitor patients receiving Kcentra, and inform them of signs and symptoms of thromboembolic events. Kcentra was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. Kcentra might not be suitable for patients with thromboembolic events in the prior 3 months.

Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). Kcentra is also contraindicated in patients with disseminated intravascular coagulation. Because Kcentra contains heparin, it is contraindicated in patients with heparin-induced thrombocytopenia (HIT).

Hypersensitivity reactions to Kcentra may occur. If patient experiences severe allergic or anaphylactic type reactions, discontinue administration and institute appropriate treatment.

In clinical trials, the most frequent (≥2.8%) adverse reactions observed in subjects receiving Kcentra were headache, nausea/vomiting, hypotension, and anemia. The most serious adverse reactions were thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.

Kcentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

Please see full prescribing information for Kcentra.

Kcentra is manufactured by CSL Behring GmbH and is distributed by CSL Behring LLC.
Kcentra ^® is a registered trademark of CSL Behring GmbH.
Biotherapies for Life^® is a registered trademark of CSL Behring LLC.
©2017 CSL Behring LLC. 1020 First Ave PO Box 61501
King of Prussia, PA 19406-0901 USA www.cslbehring-us.com www.kcentra.com
KCT-0061-MAY17 06/2021